Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Aug 12, 2016
Insider Transaction Report
Form 4
KOUSKY KENNETH W
Director
Transactions
- Other
Common Stock
2016-08-10$6.71/sh+10,439$70,003→ 105,878 total(indirect: By LLC) - Purchase
Common Stock
2016-08-10$10.00/sh+1,000$10,000→ 1,000 total - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By LLC)Exercise: $6.71→ Common Stock (116,891 underlying) - Conversion
Common Stock
2016-08-10+95,439→ 95,439 total(indirect: By LLC) - Conversion
Common Stock
2016-08-10$6.71/sh+116,891$783,859→ 116,891 total(indirect: By LLC) - Conversion
Series A Convertible Preferred Stock
2016-08-10−95,439→ 0 total(indirect: By LLC)→ Common Stock (95,439 underlying)
Footnotes (5)
- [F1]The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
- [F2]Mr. Kousky, as the Manager of BWA Gemphire Investment Group, LLC ("BWA"), beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities held by BWA except to the extent of his pecuniary interest therein.
- [F3]Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
- [F4]Mr. Kousky, as the Manager of BWA Gemphire Investment Group II, LLC ("BWA II"), beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities held by BWA II except to the extent of his pecuniary interest therein.
- [F5]The notes were issued in the original principal amount of $746,500. The outstanding principal and $37,367 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.